To include your compound in the COVID-19 Resource Center, submit it here.

Corlux mifepristone: Additional Phase III data

Additional data from the subgroup of glucose intolerant patients with endogenous Cushing's syndrome (n=29) in the open-label, U.S. Phase III SEISMIC trial in 50 patients showed that once-daily oral Corlux significantly reduced mean HbA1c

Read the full 340 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers